drugset / Trial / NCT00132405

Study of ALGRX 3268 for Needlestick Pain in Children

NCT00132405

Phase 2 Completed 260 enrolled AlgoRx Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Minor needlestick procedures often cause significant pain and distress in children, yet interventions to reduce pain are used infrequently. ALGRX 3268 is a novel, single-use, prefilled, needle-free dispenser that immediately delivers powdered lidocaine into the epidermis and provides local analgesia in 2 to 3 minutes. The purpose of this prospective, randomized, double-blind, and placebo-controlled trial is to determine the efficacy and tolerability of ALGRX 3268 in children aged 3 to 18 years undergoing venipuncture. The trial will enroll a total of 306 children aged 3 to 18 years scheduled to undergo venipuncture of the back of the hand at a single study center.

Timeline

Start
2004-05
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 0.5 mg Other

Indications

No indication recorded.